Direkt zum Inhalt
Merck
Alle Fotos(3)

Key Documents

View All Documentation

SAB4200778

Sigma-Aldrich

Anti-NRAS (internal) antibody produced in rabbit

affinity isolated antibody

Synonym(e):

Anti-GTPase NRas, Anti-transforming protein N-Ras

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(3)

About This Item

UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

rabbit

Qualitätsniveau

200

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Mol-Gew.

predicted mol wt ~21 kDa

Speziesreaktivität

human

Konzentration

~1.0 mg/mL

Methode(n)

immunoblotting: 2.5-5 μg/mL using human MCF7 cell line extract
immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human melanoma sections

UniProt-Hinterlegungsnummer

P01111

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... NRAS(4893)

Allgemeine Beschreibung

NRAS, also known as GTPase NRas, Transforming protein N-Ras, or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family, together with KRAS (Kirsten RAS), and HRAS (Harvey RAS), comprising a family of low-molecular-weight GTPases. The Ras family is named for a retrovirus that induced rat sarcomas that were later found to have activating RAS mutations. Ras family proteins serve as molecular switches in regulating pathways that are responsible for diverse cellular processes such as proliferation, differentiation, migration, and apoptosis.3 Ras proteins are highly homologous regarding their primary amino acid sequence and the differences among them concentrated in their C-terminal region. Anti-NRAS (internal) antibody produced in rabbit specifically recognizes human NRAS and does not cross-react with KRAS.

Immunogen

Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH

Anwendung

The antibody may be used in various immunochemical techniques including immunoblotting (predicted ∼21 kDa) and immunohistochemistry. Detection of the NRAS band by Immunoblotting is specifically inhibited by the immunizing protein.

Physikalische Form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as preservative.

Sonstige Hinweise

This product is for R&D use only, not for drug, household, or other uses.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Ahmed A Samatar et al.
Nature reviews. Drug discovery, 13(12), 928-942 (2014-12-02)
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.